Giorgio V. Scagliotti, MD, PhD

Giorgio V. Scagliotti, MD, PhD, head, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses treating epidermal growth factor receptor- (EGFR) mutated tumors with afatinib.

Giorgio V. Scagliotti, MD, PhD, Head, from the University of Turin, Italy, discusses toxicities related to chemotherapy and surgery in patients with lung cancer.

Dr. Giorgio Scagliotti, from the University of Turin, San Luigi Hospital, on Combining Targeted Therapies With Chemotherapy for Lung Cancer Patients.

Dr. Giorgio Scagliotti from the University of Turin Gives 3 Important Lung Cancer Takeaway Points

Dr. Giorgio Scagliotti from University of Turin Discusses Elderly Lung Cancer Therapy

Dr. Giorgio Scagliotti from the University of Turin Discusses the Future of Multiple Gene Profiles

Dr. Giorgio V. Scagliotti from the University of Turin on Mechanisms of Resistance to EGFR TKIs

Dr. Giorgio Scagliotti from the University of Turin in Italy on EGFR Targeted Therapy Survival Benefits

Dr. Giorgio Scagliotti from University of Turin Discusses EGFR Mutations in non-small cell lung cancer

Dr. Giorgio Scagliotti from the University of Turin on Tailored Treatment and the Cancer Genome

Dr. Giorgio V. Scagliotti from the University of Turin Discusses the Future of Lung Cancer Therapy

Dr. Giorgio V. Scagliotti from the University of Turin Discusses Personalizing Care With Pemetrexed